peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GLP-1/GIP/glucagon triple receptor agonist

Retatrutide

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Retatrutide is grouped with GLP-1 receptor agonists in the context of potential therapy for diabetic nephropathy. The study experimentally assessed retatrutide’s anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using both in vitro (HK-2) and in vivo (murine UUO and aging) models. The titration schedule starts with a once-weekly 2.5 mg dose (0.19 mL) for weeks 1–4. The warning lists pregnancy and breastfeeding as conditions where use should not occur.

Sources for this introduction: [1] [2] [3] [4]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Retatrutide is grouped with GLP-1 receptor agonists in the context of potential therapy for diabetic nephropathy.

Sources[5]pubmedComparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy[4]pubmedAnti-Obesity Medications in Longevity and Aesthetic Medicine.the triple agonist retatrutide
Source records
2
Independent studies
2

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy”

    Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. · Abstract

    pubmed:42630988:ae9557eb9afd:ae9557eb9afd
  2. supports · Source-backed record
    “the triple agonist retatrutide”

    Anti-Obesity Medications in Longevity and Aesthetic Medicine. · Abstract

    pubmed:42590128:7c35f98fc7c9:7c35f98fc7c9

Identity

The kit’s active drug is retatrutide, provided as 10 mg of lyophilized (freeze-dried) powder.

Sources[2]dailymeddailymed-lead-425d04f6Retatrutide 10 mg (lyophilized powder)
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Retatrutide 10 mg (lyophilized powder)”

    dailymed-lead-425d04f6 · Active ingredients (in each kit)

    dailymed:425d04f6-6fb2-5c7a-e063-6394a90aa87d:7498b2149245:7498b2149245

Identity

The kit contains a separate diluent vial: 1 mL Sterile Water for Injection for reconstitution.

Sources[2]dailymeddailymed-lead-425d04f6Sterile Water for Injection 1 mL
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Sterile Water for Injection 1 mL”

    dailymed-lead-425d04f6 · Active ingredients (in each kit)

    dailymed:425d04f6-6fb2-5c7a-e063-6394a90aa87d:7498b2149245:7498b2149245

Identity

Retatrutide is a peptide drug administered by injection that acts as an agonist at GLP-1, GIP, and glucagon receptors (GLP-1R, GIPR, and glucagon receptor).

Sources[3]pubmedThe role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.Retatrutide is an injectable peptide agonist of GLP-1R, GIPR, and the glucagon receptor
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Retatrutide is an injectable peptide agonist of GLP-1R, GIPR, and the glucagon receptor”

    The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity. · Abstract

    pubmed:42556625:f4ae8152ff92:f4ae8152ff92

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

Study findings

The study experimentally assessed retatrutide’s anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using both in vitro (HK-2) and in vivo (murine UUO and aging) models.

Sources[5]pubmedComparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models.”

    Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. · Abstract

    pubmed:42630988:ae9557eb9afd:ae9557eb9afd

Risks and interactions

Risks, organized for scanning.

Contraindications

The warning states a non-use condition based on past recurrent or severe hypoglycemia.

Sources[1]dailymeddailymed-lead-42498beeDo not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia.”

    dailymed-lead-42498bee · Warnings

    dailymed:42498bee-d406-178b-e063-6394a90a053d:71b82ac50fc8:71b82ac50fc8

Contraindications

The warning lists pregnancy and breastfeeding as conditions where use should not occur.

Sources[1]dailymeddailymed-lead-42498beePregnancy and breastfeeding: Do not use if pregnant or breastfeeding.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Pregnancy and breastfeeding: Do not use if pregnant or breastfeeding.”

    dailymed-lead-42498bee · Warnings

    dailymed:42498bee-d406-178b-e063-6394a90a053d:71b82ac50fc8:71b82ac50fc8

Products and regulatory status

Same ingredient. Different records.

Regulatory status

The product’s stated purpose classifies it as an antidiabetic and weight-management agent.

Sources[1]dailymeddailymed-lead-42498beeAntidiabetic / Weight management agent
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Antidiabetic / Weight management agent”

    dailymed-lead-42498bee · Purpose

    dailymed:42498bee-d406-178b-e063-6394a90a053d:71b82ac50fc8:71b82ac50fc8

Administration context

The practical clinical context.

Dose records

The titration schedule starts with a once-weekly 2.5 mg dose (0.19 mL) for weeks 1–4.

Sources[1]dailymeddailymed-lead-42498beeWeeks 1–4 0.19 mL (2.5 mg) once weekly
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Weeks 1–4 0.19 mL (2.5 mg) once weekly”

    dailymed-lead-42498bee · Titration schedule:

    dailymed:42498bee-d406-178b-e063-6394a90a053d:71b82ac50fc8:71b82ac50fc8

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, interaction, mechanism, safety
  • 24 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (11), assurance_score_below_0.72 (13), current_regulatory_source_required (4), extraction_ambiguity (24), high_risk_requires_regulatory_or_two_independent_sources (13), no_direct_support (24)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. dailymed-lead-42498bee ↗

    dailymed · published 2025-10-29 · retrieved 2026-09-04T22:24:46Z

  2. dailymed-lead-425d04f6 ↗

    dailymed · published 2025-10-30 · retrieved 2026-09-04T22:24:46Z

  3. The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity. ↗

    pubmed · published 2026-09-01 · retrieved 2026-08-27T11:42:45Z

  4. Anti-Obesity Medications in Longevity and Aesthetic Medicine. ↗

    pubmed · published 2026-08-03 · retrieved 2026-08-18T20:56:12Z

  5. Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. ↗

    pubmed · published 2026-09-18 · retrieved 2026-08-25T08:29:46Z

Publication history and provenance

Version 4 · Automated assessment · 2026-09-04T22:24:46Z

d004e48cff59409696df83ac48be90508fbfd69576de7fda441e5ae31e247d19